S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
NASDAQ:ZLAB

Zai Lab Stock Forecast, Price & News

$119.86
-1.01 (-0.84 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$119.14
$122.10
50-Day Range
$116.00
$161.62
52-Week Range
$75.41
$193.54
Volume518,139 shs
Average Volume502,948 shs
Market Capitalization$11.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.11
30 days | 90 days | 365 days | Advanced Chart
Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.


Zai Lab logo

About Zai Lab

Zai Lab Ltd. is a biopharmaceutical company. It engages in the discovering, licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need in the fields of oncology, infectious, and autoimmune diseases. The firm's products include Zejula and Optune. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

374th out of 1,352 stocks

Pharmaceutical Preparations Industry

181st out of 666 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab
or view top-rated stocks.

What stocks does MarketBeat like better than Zai Lab?

Wall Street analysts have given Zai Lab a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zai Lab wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) posted its earnings results on Monday, August, 9th. The company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($1.55) by $0.21. The company earned $36.94 million during the quarter, compared to analysts' expectations of $24.20 million.
View Zai Lab's earnings history
.

How has Zai Lab's stock price been impacted by Coronavirus (COVID-19)?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZLAB shares have increased by 139.1% and is now trading at $119.86.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZLAB?

4 analysts have issued 12 month price targets for Zai Lab's stock. Their forecasts range from $111.00 to $250.00. On average, they anticipate Zai Lab's stock price to reach $199.85 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price.
View analysts' price targets for Zai Lab
or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:
  • Ying Du, Chairman & Chief Executive Officer (LinkedIn Profile)
  • Tao Fu, President, Chief Operating Officer & Director
  • Billy Cho, Chief Financial Officer
  • Ning Xu, Executive VP & Head-Clinical Operations
  • James Yan, Chief Operating Officer-Research & Development

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (4.65%), Baillie Gifford & Co. (4.26%), BlackRock Inc. (4.11%), Brilliance Asset Management Ltd. (3.31%), Vanguard Group Inc. (2.24%) and Federated Hermes Inc. (2.14%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho and Ying Du.
View institutional ownership trends for Zai Lab
.

Which major investors are selling Zai Lab stock?

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Credit Suisse AG, Indus Capital Partners LLC, Bamco Inc. NY, Mackenzie Financial Corp, Schonfeld Strategic Advisors LLC, Tobam, and California Public Employees Retirement System. Company insiders that have sold Zai Lab company stock in the last year include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho, and Ying Du.
View insider buying and selling activity for Zai Lab
or view top insider-selling stocks.

Which major investors are buying Zai Lab stock?

ZLAB stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., FMR LLC, TT International Asset Management LTD, Axiom Investors LLC DE, Brilliance Asset Management Ltd., Clearbridge Investments LLC, Allianz Asset Management GmbH, and Van ECK Associates Corp.
View insider buying and selling activity for Zai Lab
or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $119.86.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $11.44 billion and generates $48.96 million in revenue each year. The company earns $-268,900,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Zai Lab have?

Zai Lab employs 2,020 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

Where are Zai Lab's headquarters?

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 862161632588 or via email at [email protected].


This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.